# Safety and Feasibility of CIK Cell Therapy in HCC After Tumor Resection

> **NCT07709299** · EARLY_PHASE1 · NOT_YET_RECRUITING · sponsor: **Royan Institute** · enrollment: 6 (estimated)

## Conditions studied

- Hepatocellular Carcinoma (HCC)

## Interventions

- **BIOLOGICAL:** Autologous Cytokine-Induced Killer (CIK) Cells

## Key facts

- **NCT ID:** NCT07709299
- **Lead sponsor:** Royan Institute
- **Sponsor class:** OTHER_GOV
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07
- **Primary completion:** 2028-07
- **Final completion:** 2028-07
- **Target enrollment:** 6 (ESTIMATED)
- **Last updated:** 2026-07-16

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07709299

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07709299, "Safety and Feasibility of CIK Cell Therapy in HCC After Tumor Resection". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07709299. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*